Fortrea to Acquire Worldwide Clinical Trials’ Early Phase Unit
DURHAM, N.C. and RESEARCH TRIANGLE PARK, N.C., September 2, 2026 Fortrea has entered into a definitive agreement to acquire...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
DURHAM, N.C. and RESEARCH TRIANGLE PARK, N.C., September 2, 2026 Fortrea has entered into a definitive agreement to acquire...
BOSTON, July 27, 2026 HoneyNaps has officially registered as a Contract Research Organization (CRO) with the Korea National Enterprise...
ZURICH, Switzerland, July 2, 2026 VERAXA Biotech AG announced the initiation of cell line development for its lead BiTAC®...
BAAR, Switzerland, June 30, 2026 Novocure has achieved a significant milestone in cancer treatment with the CE Mark approval...
CARY, N.C., June 30, 2026 Allucent, a global specialty Contract Research Organization (CRO) serving small and mid-sized biopharmaceutical companies,...
CHICAGO, Ill., June 20, 2026 Avance Clinical, a leading global Contract Research Organization (CRO) specializing in accelerating clinical development...
SHANGHAI and WATERTOWN, Mass., Jan. 1, 2026 — ChemPartner, a global contract research organization (CRO) serving the biopharmaceutical industry,...
